US EditionPublished • loading... • Updated
Burning Rock Reports Unaudited Fourth Quarter and Full Year 2025 Financial Results
Burning Rock achieved a 4.6% revenue increase to RMB539.6 million (US$77.2 million) in 2025 with a 76.6% non-GAAP gross margin amid key patent and regulatory approvals.
- On March 12, 2026, Burning Rock Biotech Limited reported unaudited financial results for the year ended December 31, 2025, and announced the USPTO granted its core ELSA-seq patent .
- After a reorganization, the company cut operating expenses to RMB457.8 million for 2025 and research and development expenses to RMB166.5 million, driven by reorganization and budget control measures.
- The company ended the year with RMB481.1 million in cash, a Q4 net loss of RMB15.4 million, a full-year net loss of RMB55.3 million, and RMB413.5 million non-GAAP gross profit with a 76.6% margin.
- The patent grant and a December presentation at Annals of Surgery show Burning Rock Biotech Limited made technical progress with ELSA-seq and RMB51.0 million in in-hospital revenue.
- Shifts in revenue mix show the company cited budget controls including headcount reduction as drivers of efficiency, with research and development expenses decreasing for the three months ended December 31, 2025.
Insights by Ground AI
39 Articles
39 Articles
Filana Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
AUSTIN, Texas, March 12, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (formerly Cassava Sciences, Inc.) (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company focused on developing novel medicines to modulate the filamin A protein for the treatment of central…
Coverage Details
Total News Sources39
Leaning Left9Leaning Right3Center12Last UpdatedBias Distribution50% Center
Bias Distribution
- 50% of the sources are Center
50% Center
L 38%
C 50%
12%
Factuality
To view factuality data please Upgrade to Premium
